The present study was designed to investigate the cardioprotective effect of animal grade piperazine citrate on isoproterenol-induced myocardial infarction in rats by studying cardiac marker enzymes and histopathological changes of the cardiac muscle. Isoproterenol administration showed significant (P<0.001) increase in the serum levels of cardiac injury markers (creatine kinase-MB and troponin-I), 358.98 ± 7.68 iu/l and 13.16 ± 0.35 ng/ml compared to the normal control group of 291.58 ± 3.56 iu/l and 9.66 ± 0.20 ng/ml respectively. Pretreatment with 15 and 30 mg/kg body weight of piperazine citrate showed a decrease in the troponin-I levels when compared with the isoproterenol group; 13.16 ± 0.35 to 12.39 ± 0.22 ng/ml in the group that received 15 mg/kg piperazine citrate (p = 0.0881) and 13.16 ± 0.35 to 11.79 ± 0.30 ng/ml (p = 0.0132) in case of the group pretreated with 30 mg/kg piperazine citrate. With regards to CK-MB, the treated groups with piperazine citrate 15 and 30 mg/kg body weight showed a reduction in the values, 340.76 ± 5.10 (p = 0.0763) and 344.17 ± 8.24 iu/l (p = 0.2178) respectively, compared to the isoproterenol group value of 358.98 ± 7.68 iu/l. Histopathological investigation showed that there was no significant architectural changes in the normal control group that received only normal saline. Structural aberrations caused by isoproterenol were also significantly reduced in the piperazine citrate treated groups. Therefore, the results of the present study suggest that low dose piperazine citrate has a significant effect on the protection of the heart.
Key words: Piperazine citrate, myocardial infarction, histopathology, Wistar rat.
Copyright © 2020 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0